Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.67 |
| ▸ | CA2 | P00918 | 3/20 | 0.67 |
| ▸ | CA12 | O43570 | 2/20 | 0.67 |
| ▸ | CA7 | P43166 | 2/20 | 0.67 |
| ▸ | CA9 | Q16790 | 2/20 | 0.67 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.67 |
| ▸ | ABL1 | P00519 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 4/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | P2RX1 | P51575 | 5/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | KCNMA1 | Q12791 | 2/20 | 0.54 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.54 |
| ▸ | TMPRSS4 | Q9NRS4 | 3/20 | 0.53 |
| ▸ | P2RX4 | Q99571 | 2/20 | 0.53 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.53 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.53 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.53 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetamide SCHEMBL7397473 | 0.93 | CA1 (0.59) | CA1CA2CA12CA7CA9 | |
| SCHEMBL1058422 | 0.85 | CA12 (0.67) | CA1CA2CA12CA7CA9 | |
| SCHEMBL32662867 | 0.85 | CA12 (0.67) | CA1CA2CA12CA7CA9 | |
| SCHEMBL6100118 | 0.84 | ABL1 (0.70) | CA1CA2CA12CA7CA9 | |
| SCHEMBL11295587 | 0.83 | KDM4E (0.62) | CA1CA2CA12CA7CA9 | |
| SCHEMBL4363906 | 0.82 | ABL1 (0.62) | ABL1LMNAKDM4EALDH1A1TSHR | |
| SCHEMBL1549062 | 0.82 | KCNMA1 (0.51) | CA1CA2CA12CA7CA9 | |
| SCHEMBL1115036 | 0.81 | CA1 (0.56) | CA1CA2CA12CA7CA9 | |
| SCHEMBL17913440 | 0.81 | ABL1 (0.53) | CA1CA2CA12CA7CA9 | |
| SCHEMBL4308995 | 0.81 | ABL1 (0.61) | CA1CA2CA12CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 601 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110563721-A | Preparation method of azasetron hydrochloride | 成都大学 | 2019-12-13 | — | — | CN | claimed |
| CN-109678830-A | A kind of trimethoxy flavone salicyclic acid derivatives and its anti-tumor activity | 南华大学 | 2019-04-26 | — | — | CN | claimed |
| EP-4294800-B1 | APOL1 INHIBITORS AND METHODS OF USE | MAZE THERAPEUTICS INC (US) | 2026-05-06 | — | — | EP | disclosed |
| EP-4713320-A2 | BCAT2 INHIBITORS | Agios Pharmaceuticals, Inc. (US) | 2026-03-25 | — | — | EP | disclosed |
| US-12576055-B2 | Disease detection and treatment based on trimethyl-lysine levels | THE CLEVELAND CLINIC FOUNDATION (US) | 2026-03-17 | — | — | US | disclosed |
| EP-3558298-B1 | ANTIDIABETIC SPIROCHROMAN COMPOUNDS | MERCK SHARP & DOHME LLC (US) | 2026-03-11 | — | — | EP | disclosed |
| US-20260055083-A1 | APOL1 INHIBITORS AND METHODS OF USE | MAZE THERAPEUTICS INC (US) | 2026-02-26 | — | — | US | disclosed |
| US-12459929-B2 | GPCR receptor agonists, pharmaceutical compositions comprising the same, and methods for their use | CARMOT THERAPEUTICS INC. (US) | 2025-11-04 | — | — | US | disclosed |
| US-12441703-B2 | Carboxamides as modulators of sodium channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-10-14 | — | — | US | disclosed |
| EP-4605409-A2 | CYCLIN INHIBITORS | Circle Pharma, Inc. (US) | 2025-08-27 | — | — | EP | disclosed |
| EP-4573077-A1 | APOL1 INHIBITORS AND METHODS OF USE | Maze Therapeutics, Inc. (US) | 2025-06-25 | — | — | EP | disclosed |
| EP-0107804-A1 | 3-Methylflavone-8-carboxylic acid derivatives and process for the preparation of the same | Yamamoto Chemical Industrial Company, Limited (JP) | 1984-05-09 | — | — | EP | disclosed |
| EP-0105484-A2 | 3-Propionylsalicyclic acid derivatives and process for the preparation of the same | Yamamoto Chemical Industrial Company, Limited (JP) | 1984-04-18 | — | — | EP | disclosed |
| EP-0018830-B1 | SPIROBENZOFURANONES, THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Takeda Chemical Industries, Ltd. (JP) | 1983-06-08 | — | — | EP | disclosed |
| EP-0003084-B1 | SPIROBENZOFURANONE COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS MEDICINES | Takeda Chemical Industries, Ltd. (JP) | 1982-02-24 | — | — | EP | disclosed |
| US-4284644-A | Spirobenzofuranone compounds | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1981-08-18 | — | — | US | disclosed |
| US-4281012-A | HYPOLIPEMIC ACTIVITY | ROUSSEL UCLAF (FR) | 1981-07-28 | — | — | US | disclosed |
| EP-0018830-A2 | Spirobenzofuranones, their production and pharmaceutical compositions containing them | Takeda Chemical Industries, Ltd. (JP) | 1980-11-12 | — | — | EP | disclosed |
| EP-0003084-A1 | Spirobenzofuranone compounds, processes for their preparation and their use as medicines | Takeda Chemical Industries, Ltd. (JP) | 1979-07-25 | — | — | EP | disclosed |
| US-3965173-A | MULTISTAGE, METHYLATION OF 5-CHLOROSALICYLIC ACID | CHUBB FRANCIS L | 1976-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12459929-B2 | GPCR receptor agonists, pharmaceutical compositions comprising the same, and methods for their use | GLP1R, GCGR, GIPR | CA1 4627/4885CA2 2671/4885CA12 4411/4885 |
| US-12441703-B2 | Carboxamides as modulators of sodium channels | TRPV1, SCN2A, SCN10A | CA1 646/4885CA2 105/4885CA12 1279/4885 |
| US-12576055-B2 | Disease detection and treatment based on trimethyl-lysine levels | BHMT, BHMT2, EHMT2 | CA1 2402/4885CA2 1446/4885CA12 1832/4885 |
| US-20260055083-A1 | APOL1 INHIBITORS AND METHODS OF USE | APOL1, LDLR, APOB | CA1 4644/4885CA2 4741/4885CA12 4749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.